Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 38 of 271 for:    Recruiting, Not yet recruiting, Available Studies | "Lower Urinary Tract Symptoms"

Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02167009
Recruitment Status : Recruiting
First Posted : June 18, 2014
Last Update Posted : May 20, 2019
Sponsor:
Information provided by (Responsible Party):
Tampa General Hospital

Brief Summary:
Study to evaluate Prostate Artery Embolization for the treatment of lower urinary track symptoms due to Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams.

Condition or disease Intervention/treatment Phase
Benign Prostatic Hyperplasia Device: Embosphere Microspheres Not Applicable

Detailed Description:

This is a phase II, single center, prospective, single arm, investigational study to evaluate the safety and efficacy of prostate artery embolization (PAE) for treatment of severe lower urinary tract symptoms (LUTS) related to BPH in patients with prostate size greater than 90 grams that either refuse surgical treatment or are considered poor candidates for traditional surgical therapy.

30 patients will be enrolled in the single treatment arm with follow-up for no less than 12 months.

The study will involve a screening period in which patient eligibility will be determined. Once eligibility is confirmed, patients will receive PAE with Embosphere Microspheres within 4 weeks of screening and transrectal ultrasound. After treatment, patients will return for follow-up visits at 1 month, 3 months, 6 months, and 12 months post PAE. At each of these visits, patients will complete IPSS and IIEF questionnaires, undergo a physical exam, and perform a medication review. Repeat TRUS and urodynamic testing will be performed at the 6 month and 12 month post PAE follow-up visit.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II, Single Arm Prospective Study to Evaluate Safety and Efficacy of Prostate Artery Embolization in Patients With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams
Study Start Date : December 2014
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Prostate Artery Embolization
Embospheres microspheres
Device: Embosphere Microspheres
Embosphere Microspheres are indicated for use in embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.




Primary Outcome Measures :
  1. Improvement of BPH symptoms as assessed by the IPSS at 12 months post PAE. [ Time Frame: Safety will be evaluated throughout the initial 12 months of the study by assessing adverse events and findings on physical examination. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is aged 50-85 years
  • Patient has signed informed consent
  • Patient has experienced lower urinary tract symptoms (LUTS) for at least 1 year prior to study enrollment
  • Patient has a prostate size larger than 90g as measured by transrectal ultrasound (TRUS)
  • Patient has an IPSS score greater than or equal to 13
  • Patient has a peak urine flow rate < 12 mL/sec
  • Patient either:
  • Refuses surgical treatment
  • Is considered high risk for surgical treatment
  • Patient is either:
  • Refractory to medical treatment
  • Contraindicated for medical treatment
  • Patient must meet ONE of the following criteria:
  • Baseline PSA ≤ 2.5ng/mL
  • Baseline PSA > 2.5 ng/mL and ≤ 10 ng/mL AND free PSA ≥ 25% of total PSA (no biopsy required)
  • Baseline PSA > 2.5 ng/mL and ≤ 10 ng/mL AND free PSA < 25% of total PSA AND negative prostate biopsy result (minimum of 12 core biopsy) within 12 months
  • Baseline PSA >10 ng/mL AND negative prostate biopsy result (minimum of 12 core biopsy) within 12 months

Exclusion Criteria:

  • History of prostate or bladder cancer, or currently being evaluated for cancer
  • History of prostate or bladder cancer, or currently being evaluated for cancer
  • Patient has taken alpha blockers within 4 weeks of screening
  • Patient has experienced an irregular voiding pattern despite medical management with a stable 5-alpha reductase inhibitor dosage for 3 months or longer
  • History of open prostate surgery, radiofrequency, or microwave therapy
  • Previous open bladder or rectosigmoid colon surgery
  • TURP within the last two years
  • Patient has nodularity or induration detected upon digital rectal examination (DRE)
  • Neurogenic bladder or other neurological disorder impacting bladder function
  • Urethral stricture, bladder neck contracture, other potentially confounding bladder pathology, bladder disease, or confounding urethral pathology
  • Acute urinary retention requiring an indwelling catheter
  • Bladder atonia
  • Active prostatitis or urinary tract infection
  • Cystolithiasis within the past 3 months
  • Serum creatinine >1.7mg/dL
  • Coagulation disturbances not normalized by medical treatment
  • Iodinated contrast allergy not controlled with 24-hour steroid preparation
  • History of gelatin allergy
  • History of pelvic irradiation
  • History of severe peripheral vascular disease or known major iliac arterial occlusive disease
  • History of smoking greater than 30 pack-years
  • Interest in future fertility
  • Significant cardiac or respiratory disease that the Investigator believes puts the patient at risk for a complication during the procedure
  • Any other risks or factors that the Investigator believes puts the patient at risk for a complication during the procedure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02167009


Contacts
Layout table for location contacts
Contact: Michelle Hughes, RN PAE@tgh.org

Locations
Layout table for location information
United States, Florida
Tampa General Hospital Recruiting
Tampa, Florida, United States, 33606
Sponsors and Collaborators
Tampa General Hospital
Investigators
Layout table for investigator information
Principal Investigator: Cliff Davis, MD Tampa General Hospital

Layout table for additonal information
Responsible Party: Tampa General Hospital
ClinicalTrials.gov Identifier: NCT02167009     History of Changes
Other Study ID Numbers: TGH0003
First Posted: June 18, 2014    Key Record Dates
Last Update Posted: May 20, 2019
Last Verified: May 2019

Keywords provided by Tampa General Hospital:
ARTERY EMBOLIZATION
BPH

Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperplasia
Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Pathologic Processes
Prostatic Diseases
Genital Diseases, Male
Urological Manifestations
Signs and Symptoms